Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast

Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News23 hours ago
‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours ago
Developer warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours ago
Older Aussies back increased superannuation tax
-
Noosa News20 hours ago
Tips to improve engagement – Proctor